Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.50 |
| ▸ | PTGFR | P43088 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9663068 | 0.96 | HDAC1 (0.60) | CYP1A2HDAC1HDAC6MTNR1AMTNR1B | |
| SCHEMBL7332474 | 0.89 | TAAR1 (0.61) | HDAC1HDAC6MTNR1AMTNR1BRAB9A | |
| SCHEMBL29669893 | 0.88 | HDAC1 (0.63) | CYP1A2HDAC1HDAC6MTNR1AMTNR1B | |
| SCHEMBL7758273 | 0.88 | HDAC1 (0.63) | CYP1A2HDAC1HDAC6MTNR1AMTNR1B | |
| SCHEMBL346302 | 0.88 | FFAR1 (0.65) | CYP1A2HDAC1HDAC6MTNR1AMTNR1B | |
| SCHEMBL28188589 | 0.87 | HDAC1 (0.70) | CYP1A2HDAC1HDAC6MTNR1AMTNR1B | |
| SCHEMBL1206248 | 0.87 | HDAC1 (0.70) | CYP1A2HDAC1HDAC6MTNR1AMTNR1B | |
| SCHEMBL7317315 | 0.86 | EPHX2 (0.62) | CYP1A2HDAC1HDAC6MTNR1AMTNR1B | |
| SCHEMBL25035334 | 0.85 | HDAC1 (0.72) | CYP1A2HDAC1HDAC6MTNR1AMTNR1B | |
| SCHEMBL9663074 | 0.85 | HDAC1 (0.72) | CYP1A2HDAC1HDAC6MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168145-A1 | FUSED IMIDAZOLE DERIVATIVES AND USE THEREOF AS ALDOSTERONE SYNTHASE INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2010-07-01 | — | — | US | disclosed |
| EP-1885359-A1 | FUSED IMIDAZOLE DERIVATIVES AND USE THEREOF AS ALDOSTERONE SYNTHASE INHIBITORS | Speedel Experimenta AG (CH) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006128851-A1 | FUSED IMIDAZOLE DERIVATIVES AND USE THEREOF AS ALDOSTERONE SYNTHASE INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168145-A1 | FUSED IMIDAZOLE DERIVATIVES AND USE THEREOF AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | CYP1A2 42/4885HDAC1 744/4885HDAC6 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.